secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001493152-24-047085
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML
--------------------------------------------------------------------------------

- Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.
- Budget up to ~$2 million over three years, funded entirely by GT Biopharma.
- University of Minnesota sponsors the IND and acts as sponsor-investigator; Company supplies study drug and funding.
- Study data owned by University; Company may use data subject to consent and laws; each party may publish results.
- Agreement terminable on 30 days' notice by either party, or immediately for safety reasons.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315224047085/0001493152-24-047085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315224047085/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer